- Travere Therapeutics' FILSPARI is the first and only FDA-approved medicine for FSGS.
- The approval is expected to be a major revenue driver for the company.
- FILSPARI's sole-approved status for FSGS gives it a significant market advantage.
戻る
戻る
Travere Therapeutics Surges on Full FDA Approval for FSGS Drug FILSPARI
Travere Therapeutics Inc. ($TVTX) has received full approval from the U.S. Food and Drug Administration for FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The decision, announced on April 13, 2026, makes FILSPARI the first and only medicine to be approved for this condition.
"This is a transformative moment for the FSGS community and for Travere," said Eric Dube, Ph.D., President and CEO of Travere Therapeutics. "We are proud to bring the first and only approved non-immunosuppressive therapy to FSGS patients."
The full approval was granted based on the positive outcomes from the pivotal Phase 3 DUPLEX Study. The study demonstrated that treatment with FILSPARI resulted in a statistically significant reduction in proteinuria, a key marker of kidney damage in FSGS, when compared to a control group. This data underscores the drug's efficacy in a patient population that has had no approved treatment options.
The approval of FILSPARI is expected to be a major revenue driver for Travere Therapeutics, with analysts forecasting peak sales to exceed $1 billion. As the sole approved treatment for FSGS, FILSPARI is positioned to capture a significant market share, likely leading to a positive re-rating of the company's stock. This development sets a new standard of care in the renal disease space and may impact competitors in the field.
This article is for informational purposes only and does not constitute investment advice.